NEW YORK, Nov. 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Pharmaceutical Market: UK

http://www.reportlinker.com/p0203096/The-Pharmaceutical-Market-UK.html#u...

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 1

Snapshot: Strategic Espicom Analysis 2

Snapshot: Key Data Projections3

MACROENVIRONMENT 4

POLITICAL 4

ECONOMIC5

Projections 5

LEGAL6

EU Patent Protection & Intellectual Property Rights 6

Proposal for Unitary Patent 6

EU Supplementary Protection Certificates6

EU Data Exclusivity6

DEMOGRAPHIC 7

Projections 7

Demographic Indicators8

Births 8

Deaths 8

Infant Deaths 8

Life Expectancy at Birth 8

EPIDEMIOLOGY 9

DISEASE BURDEN 9

Leading Causes of Mortality9

DISEASE PREVALENCE10

Communicable Diseases 10

HIV/AIDS 10

Non-Communicable Diseases 11

Cancer 11

Diabetes 11

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 12

EU DIRECTIVE12

Cross-Border Healthcare Directive 12

ORGANISATION 12

Performance 12

Structure 13

Department of Health 14

Strategic Health Authorities 14

Primary Care Trusts 14

Acute Trusts 14

NHS Foundation Trusts 14

NHS Care Trusts 15

Ambulance Trusts 15

Care Quality Commission 15

EXPENDITURE 17

Projections 17

NHS Budget 18

Private Healthcare 18

INFRASTRUCTURE 19

Hospital Infrastructure19

Private Hospital Operators19

BMI Healthcare 19

HCA International 19

Netcare 19

NHS Trusts 20

Nuffield Health 20

Partnership Health Group (PHG) 20

Ramsay Healthcare20

Spire Healthcare 20

Ambulatory Infrastructure21

SERVICES 21

Hospital Inpatient Services 21

Outpatient Services22

WORKFORCE 22

Projections 22

Physicians 23

Nurses 23

Dentists 24

Pharmacists 24

REGULATORY AFFAIRS 25

EU REGULATORY AUTHORITY 25

NATIONAL AUTHORITIES 25

MARKETING REGISTRATION 26

EU Marketing Registration26

Centralised Procedure 26

National Procedures 27

IMPORT REGULATIONS 27

Parallel Trade 27

PROMOTION 28

Advertising 28

PRICING & REIMBURSEMENT 29

EU NETWORKING MEETING 29

NM CAPR29

PRICING 29

PPRS Reforms 29

Patient Access Schemes 30

Prescription Charges 31

REIMBURSEMENT 31

DISTRIBUTION CHANNELS 34

EU DIRECTIVE 34

Falsified Medicines Directive34

DRUG WHOLESALING 34

Association of Wholesalers 34

BAPW34

Leading Wholesalers 35

AAH Pharmaceuticals 35

Alliance Healthcare35

DRUG RETAILING 36

Association of Independent Pharmacies 36

Numark36

Association of Community Pharmacies36

NPA 36

Leading Pharmacy Chains 37

Alliance Boots 37

Lloydspharmacy 37

Superdrug 37

MARKET ANALYSIS 38

SIZE 38

Projections 38

Historical Figures 40

Current Structure 41

PRODUCT DEVELOPMENT 49

EU Programmes49

Horizon 2020 49

IMI 49

National Research & Development 49

MANUFACTURING 52

TRADE53

Exports 53

Imports 56

Balance of Trade 60

COMPETITION 61

TRADE ASSOCIATIONS 61

ABPI 61

COMPANY INTELLIGENCE 62

AstraZeneca62

Eisai62

Eli Lilly 62

GlaxoSmithKline 62

MSD63

Novartis 63

Pfizer 64

ProStrakan64

Shire Pharmaceuticals 65

ViiV Healthcare 65

Competitive Strategies65

GLOBAL COMPANY INTELLIGENCE 66

AstraZeneca66

Company Overview 66

Financial Performance66

Product Portfolio 67

R&D Strategy 69

Manufacturing Capabilities 71

Outlook 71

GlaxoSmithKline 72

Company Overview 72

Financial Performance72

Product Portfolio 73

R&D Strategy 75

Manufacturing Capabilities 76

Outlook 76

Shire 77

Company Overview 77

Financial Performance78

Product Portfolio 79

R&D Strategy 80

Manufacturing Capabilities 81

OTC PHARMACEUTICALS 82

REGULATION 82

Marketing Registration 82

Labelling 82

MARKET SIZE 83

COMPETITION 84

Trade Association84

PAGB 84

GENERIC PHARMACEUTICALS 85

REGULATION 85

EU Marketing Registration85

Pricing & Reimbursement 85

Generic Substitution Plans are Scrapped 85

Unbranded Generic Pricing 85

2005 Generics Reimbursement Scheme 86

MARKET SIZE 87

COMPETITION 90

Trade Association90

BGMA90

Company Intelligence 90

Actavis 90

Bristol Laboratories90

Dr Reddy's 91

Kent Pharmaceuticals 91

Pfizer 91

Rosemont Pharmaceuticals 91

Teva Pharmaceuticals 91

Winthrop Pharmaceuticals 92

Wockhardt 92

BIOLOGICS & BIOSIMILARS 93

REGULATION 93

EU Approval Process 93

EU Regulation of Biosimilars 93

EMA Guideline Documents94

Draft Biosimilar Concept Paper94

Biosimilar mAb Guideline 94

Biosimilars Approved in the EU 95

National Regulation 95

NICE Approves First Biosimilar for NHS Use95

PRODUCT DEVELOPMENT 96

Cancer Research 96

Stem Cell Research 96

COMPETITION 97

Trade Association97

BIA 97

Company Intelligence 97

Angel Biotechnology97

Argenta 97

Ark Therapeutics 98

Astex Therapeutics98

BigDNA98

BioFocus 98

Biogen Idec 98

BTG 99

Cellartis99

Convergence Pharmaceuticals 99

FMC BioPolymer 99

ImmuPharma 99

Intercell 99

Lonza 100

NovaBiotics100

Oxford BioMedica100

PolyTherics 100

Silence Therapeutics 101

UCB 101

Competitive Strategies 101

CONCLUSIONS: OPPORTUNITIES & CHALLENGES 103

Strategic Espicom Analysis 103

MACROENVIRONMENT 103

EPIDEMIOLOGY 103

HEALTHCARE103

REGULATORY AFFAIRS104

PRICING & REIMBURSEMENT 104

DISTRIBUTION CHANNELS 105

MARKET 105

COMPETITION 106

OTC PHARMACEUTICALS 106

GENERIC PHARMACEUTICALS106

BIOLOGICS & BIOSIMILARS 106

Radar Analysis 108

SWOT Analysis 108

DIRECTORY 109

GOVERNMENT ORGANISATIONS 109

PHARMACEUTICAL COMPANIES 109

Biologic Companies 109

Generic Companies 109

PHARMACEUTICAL DISTRIBUTORS110

PHARMACY CHAINS 110

TRADE ORGANISATIONS110

List of Tables

Espicom Analysis of the Pharmaceutical Market, 2012 2

Key Data Projections, 2012-2017 3

Political Landscape, 2012 4

Regional Ranking of Projected Economies, 2017 5

Projected Economy, 2012-2017 5

Regional Ranking of Projected Demographics, 2017 7

Projected Demographics, 2012-2017 7

Demographic Indicators, 2002-2009 8

Causes of Death by Country, 2010 9

HIV and AIDS Cases, up to 2010 10

Regional Ranking of Projected Health Expenditure, 2017 17

Projected Health Expenditure, 2012-201717

Inpatient Procedures and Interventions by Type, 2010/11 21

Regional Ranking of Projected Physicians, 2017 22

Projected Physicians, 2012-2017 22

Consultants by Specialty in England, 2008-2010 23

NHS Nurses by Country, 2007-2009 23

Patient Access Schemes in Published Guidance, 2007-2010 30

NICE Appraisals in Development, January 2012 31

Members of BAPW, 2011 34

Celesio's Revenue from Wholesale Activities, 2007-2009 (Euro Millions) 35

Alliance Healthcare's Financial Highlights, 2008-2010 (£ Millions) 35

Regional Ranking of Projected Pharmaceutical Markets, 2017 38

Projected Pharmaceutical Market at Retail Prices, 2012-2017 38

Historical Pharmaceutical Market at Retail Prices, 1995-2011 40

Written Prescriptions, 2006-2010 (Millions) 41

Prescriptions by Value, 2006-2010 (£ Millions) 41

Prescriptions & Cost by Therapeutic Area in the UK, 2010 42

Prescriptions & Cost by Therapeutic Area in England, 2010 43

Top 20 Prescribed Drugs in England by Value, 2010 44

Top 20 Prescribed Drugs in England by Volume, 2010 45

Cost of Pharmaceuticals Issued by Hospital Pharmacies in England, 2003-2010 (£ Millions) 45

Prescriptions & Cost by Therapeutic Area in Wales, 2010 46

Prescriptions & Cost by Therapeutic Area in Scotland, 2010 47

Prescriptions & Cost by Therapeutic Area in Northern Ireland, 201048

Pharmaceutical R&D Expenditure, 1972-2007 (£ Millions) 50

Pharmaceutical Production, 1995-2010 (Euros 000s) 52

Pharmaceutical Exports by Category, 1995-2010 (US$000s) 53

Pharmaceutical Exports by Country/Region, 2010 (US$000s) 55

Pharmaceutical Imports by Category, 1995-2010 (US$000s) 56

Imports of Raw Materials by Country/Region, 2010 (US$000s) 58

Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s) 58

Imports of Medicaments by Country/Region, 2010 (US$000s) 59

Balance of Pharmaceutical Trade, 1995-2010 (US$000s) 60

Full Members of the ABPI, 2011 61

AstraZeneca's Principal Operating Results, 2006-2010 (US$ Million) 66

AstraZeneca's Sales by Geographic Area, 2006-2010 (US$ Million) 67

AstraZeneca's Sales by Leading Products, 2006-2010 (US$ Million)68

AstraZeneca's Recent Product Approvals, 2010-2011 69

AstraZeneca's Major Manufacturing Facilities by Location, 2011 71

GSK's Principal Operating Results, 2006-2010 (£ Million) 73

GSK's Sales by Geographic Area, 2007-2010 (£ Million) 73

GSK's Sales by Leading Products, 2006-2010 (£ Million) 74

GSK's Recent Product Approvals, 2010-2011 75 Shire's Principal Operating Results, 2006-2010 (US$ Million) 78

Shire's Revenue by Business Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Geographic Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Leading Products, 2006-2010 (US$ Million) 79

Shire's Recent Product Approvals, 2010-2011 80

Shire's Major Manufacturing Facilities by Location, 2011 81

OTC Sales at Retail Prices, 2007-2010 (£ Millions) 83

Full Members of PAGB, 2011 84

Prescriptions Written and Dispensed Generically in England by Value, 1996-2010 (£ Millions) 87

Prescriptions Written and Dispensed Generically in England by Volume, 1996-2010 (Millions) 88

Generic Prescribing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 88

Generic Dispensing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 89

Members of BGMA, 2011 90

Biosimilars Approved in the EU 95

Espicom Analysis of the Pharmaceutical Market, 2012 107

SWOT Analysis of the Pharmaceutical Market, 2012 108

List of Charts

Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail Prices, 2017 39

Regional Comparison of Projected Pharmaceutical Market Share, 2017 39

Historical Pharmaceutical Market at Retail Prices, 1995-201140

Pharmaceutical Exports, 1995-2010 (US$ Billions) 54

Pharmaceutical Exports by Country/Region, 2010 (%) 54

Pharmaceutical Imports, 1995-2010 (US$ Billions) 56

Imports of Pharmaceuticals by Country/Region, 2010 (%) 57

Balance of Pharmaceutical Trade, 1995-2010 (US$ Billions)60

Radar Graph of the Pharmaceutical Market, 2012 108

To order this report:

Pharmaceutical Industry: The Pharmaceutical Market: UK

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker